ATHENA Data Presented at International Papillomavirus Conference Support Use of Roche Molecular Systems, Inc. (RHHBF.PK)’s cobas® HPV Test in Primary Screening for Cervical Cancer
12/9/2011 4:40:13 PM
Roche (SIX: RO, ROG; OTCQX: RHHBY) today highlighted data from a sub-analysis of the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) landmark study, demonstrating that HPV DNA tests, including the Roche cobas HPV Test, could be used for the primary screening of cervical cancer. The data, which was recently published online in The Lancet Oncology, was presented at the 27th annual International Papillomavirus Conference (IPV).
comments powered by